[go: up one dir, main page]

Avichezer et al., 1997 - Google Patents

Immunoreactivities of polyclonal and monoclonal anti‐T and anti‐Tn antibodies with human carcinoma cells, grown in vitro and in a xenograft model

Avichezer et al., 1997

Document ID
2480896381457389681
Author
Avichezer D
Springer G
Schechter B
Arnon R
Publication year
Publication venue
International journal of cancer

External Links

Snippet

Human polyclonal, monospecific anti‐T and‐Tn antibodies were found to be reactive in ELISA tests with human ovarian (IGROV‐1, OVCAR‐3 and SKOV‐3), breast (SKBr‐3 and T47D)‐and oral (KB)‐carcinoma cell lines, but less so or non‐reactive with normal epithelia …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate

Similar Documents

Publication Publication Date Title
Avichezer et al. Immunoreactivities of polyclonal and monoclonal anti‐T and anti‐Tn antibodies with human carcinoma cells, grown in vitro and in a xenograft model
Jin et al. The physiological and pathological roles and applications of sialyl Lewis x, a common carbohydrate ligand of the three selectins
Yuan et al. Comparison of T-antigen expression in normal, premalignant, and malignant human colonic tissue using lectin and antibody immunohistochemistry
Kannagi Carbohydrate-mediated cell adhesion involved in hematogenous metastasis of cancer
JP5468587B2 (en) Cell cytotoxicity mediating surface expression of CD44
Satoh et al. Enhanced GM3 expression, associated with decreased invasiveness, is induced by brefeldin A in bladder cancer cells
JP2007530458A (en) Cancer disease modifying antibodies
Hebbar et al. The relationship between concentrations of circulating soluble E-selectin and clinical, pathological, and biological features in patients with breast cancer.
US20060140963A1 (en) Cytotoxicity mediation of cells evidencing surface expression of CD59
Xu et al. Expression of tag‐72 in normal colon, transitional mucosa, and colon cancer
Zenita et al. Fucosylated type‐2 chain polylactosamine antigens in human lung cancer
US20080089891A1 (en) Cancerous disease modifying antibodies
US7534429B2 (en) Cytotoxicity mediation of cells evidencing surface expression of CD63
Zhang et al. Comparison of sialyl-Lewis a-carrying CD43 and MUC1 mucins secreted from a colon carcinoma cell line for E-selectin binding and inhibition of leukocyte adhesion
US6760612B2 (en) Method for detecting lymphoid tissue in tumor progression
US20080044408A1 (en) Cytotoxicity mediation of cells evidencing surface expression of CD63
Kageshita et al. Association between sialyl Lewisa expression and tumor progression in melanoma
US7431923B2 (en) Cytotoxicity mediation of cells evidencing surface expression of CD63
Matsushita et al. Expression of sulfomucins in normal mucosae, colorectal adenocarcinomas and metastases
Fattorossi et al. Constitutive and inducible expression of the epithelial antigen MUC1 (CD227) in human T cells
Yu et al. Stimulation of proliferation in human colon cancer cells by human monoclonal antibodies against the TF antigen (galactose β1‐3 N‐acetyl‐galactosamine)
JPH09502089A (en) Natural killer cell-specific antigen and antibody that identifies this antigen
Young Jr et al. Deletion of antigens of the Lewis a/b blood group family in human prostatic carcinoma
Shih et al. Distribution of cells bearing the HNK-1 epitope in the human placenta
Compton et al. Immunohistochemical studies of blood group substance H in colorectal tumors using a monoclonal antibody